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1. Introduction 
Gestational Diabetes Mellitus (GDM) is glucose intolerance first diagnosed during 
pregnancy (Metzger and Coustan 1998, World Health Organization 1999). Gestational 
diabetes is a condition that complicates 3-12.% of pregnancies (Gabbe and Graves 2003, 
Omu et al 2010 ) with wide variation in the incidence of gestational diabetes reported among 
ethnic groups.This could be newly diagnosed type 1 or type 2 Diabetes Mellitus or a new 
onset of hyperglycemia secondary to metabolic changes related to pregnancy (Yogev and 
Visser 2009). The rates of Gestational diabetes mellitus are increasing with the epidemic of 
obesity worldwide. Risk factors for GDM include advanced maternal age, multiparity, and 
racial or ethnic minority status (Table 1).  
 
 Body mass index more than 30 kg/m² 
 Previous macrosomic baby weighing 4.5 kg or more 
 Previous gestational diabetes 
 Family history of diabetes (first-degree relative with diabetes) 
 Family origin with a high prevalence of diabetes: 
 South Asian (specifically women whose country of family origin is India, 
Pakistan or 
 Bangladesh) 
 Black Caribbean 
 Middle Eastern (specifically women whose country of family origin is Saudi 
Arabia, United Arab Emirates, Iraq, Jordan, Syria, Oman, Qatar, Kuwait, 
Lebanon or Egypt) 
Reproduced from the National Institute for Health and Clinical Excellence guideline for diabetes in 
pregnancy (12) by RCOG Scientific Advisory Committee Opinion Paper 23: Diagnosis and Treatment of 
Gestational Diabetes (RCOG 2011). 
Table 1. Risk factors for Gestational diabetes mellitus 
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There are health implications for both the mother and infant who remain at risk for 
complications such as embryopathies, spontaneous abortion and perinatal mortality and 
morbidity (Loeken 2006).  
There has been considerable controversy surrounding the screening and diagnosis, natural 
history, management and outcome of women with gestational diabetes. The 2008 NICE 
guidelines (NICE 2008) on diabetes in pregnancy detailed a screening programme targeting 
biochemical screening to women with risk factors. Women with a history of gestational 
diabetes mellitus (GDM) have an increased risk for recurrence in subsequent pregnancies, 
according to the results of a population-based, retrospective cohort study (HAPO Study 
Cooperative Research Group 2008). Oxidative stress has been implicated in the pathogenesis 
and development of complications of diabetes in pregnancy (King and Loeken 2004, Loeken 
2004, Marfella et al 2001, Morgan et al 2008, Rosen et al 2001, Wender-Ozegowska et al 
2004). The role of Butyrylcholinesterase (BuChE) in the aetiology, screening and monitoring, 
complications and future drug development of Gestational Diabetes Mellitus has become an 
interesting area of speculative research (Mahmoud et al 2003, Mohmoud etal 2006, 
Mahmoud et al 2008, Rustemeijer et al 2001, Serlin et al 2009, Sternfield et al 1997). 
2. The objective 
The objective of this chapter is to elucidate the relationship between gestational diabetes 
mellitus (GDM) and BuChE in the pathogenesis, monitoring and future drug development.  
3. Pathogenesis of GDM      
The cornerstones of development of gestational diabetes mellitus are related to modern 
lifestyle, principally, a lack of exercise and an unhealthy diet, the environment and some 
degree of genetic profile (American Diabetic Association 2003, Hollander et al 2007, Serlin et 
al 2009).  Elevated glucose in pregnancy may be caused by increased levels of diabetogenic 
factors of pregnancy such as glucocorticoids, human placental lactogen and oestrogens. 
Hyperglycaemia causes oxidative stress due to increased production of mitochondrial ROS, 
nonenzymatic glycation of proteins, and glucose autoxidation (Brownlee 2001). Elevated 
FFA can also cause oxidative stress due to increased mitochondrial uncoupling and ß-
oxidation, leading to the increased production of ROS. In addition, hyperglycemia- and FFA-
induced oxidative stress leads to the activation of stress-sensitive signaling pathways (Evans 
et al 2003). This, in turn, worsens both insulin secretion and action, leading to overt 
Gestational Diabetes Mellitus. Administration of glucocorticoids significantly decreases the 
catalytic activity of BuChE in plasma and liver regardless of sex (Vrdoljaki et al 2005). 
3.1 Hyperglycemia and oxidative stress 
The pathogenic effect of hyperglycaemia is mediated to a significant extent via increased 
production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) and 
subsequent oxidative stress (King and Loeken 2004, Marfella2001, Rosen et al 2001, Wender-
Ozegowska et al 2004). ROS and RNS directly oxidize and damage DNA, proteins, and lipids 
and thus adversely affect the pancreas especially the  Langerhan cells that produce insulin. 
Similarly, there is disruption of the alpha cells that produce glucagon. The paracrine 
relationship between the pancreatic beta and alpha cells is disrupted to cause -cell 
dysfunction.  There is also growing evidence that activation of stress-sensitive pathways, such 
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as NF-kB, p38 MAPK, JNK/SAPK, and hexosamine, by elevations in glucose and possibly FFA 
levels leads to both insulin resistance and impaired insulin secretion through ß-cell 
dysfunction (Kyriakis et al 1992). Circulating serum levels of lipid peroxidation product 
malonedialdehyde (MDA) and protein oxidation markers are elevated in GDM compared to 
healthy normal pregnancy and give rise to a negatively strong correlation between MDA and 
BuChE in serum and placenta (Omu et al 2010). A third causal pathway may be through the 
induction of apoptosis of the beta cells by advanced glycation end-products. This would 
explain the varying severity of GDM among the patients.  BuChE deficiency results in delayed 
metabolism of a number of compounds of clinical significance, including glucose, thus 
contributing to the pathogenesis of diabetes mellitus.  Glucose metabolism is controlled by the 
hormone insulin produced in the pancreas. BuChE deficiency in pregnancy may be as a result 
of hereditary deficiency and haemodilution in second half of pregnancy.  
3.2 Role of estrogen receptor alpha in glucose and lipid metabolism 
The estrogen receptor ER-alpha is emerging as a key molecule involved in glucose and lipid 
metabolism. The activation of ER-alpha by physiological concentrations of E2 may play an 
important role in the adaptation of the endocrine pancreas to pregnancy. However, if ER-
alpha is over stimulated by an excess of E2 or the action of an environmental estrogen such 
as Biphenol A (Nadal et al 2009, Paloma et al 2008, Ropero et al 2008), it can result in an 
excessive insulin signaling. This may provoke insulin resistance in the liver and muscle, as 
well as beta-cell exhaustion and therefore, contribute to the development of Gestational 
Diabetes. An association between oestrogen receptor alpha and BuChE has been reported 
(Combarros et al 2007). 
3.3 Environmental factors 
The increase of endocrine-disrupting chemicals (EDCs) in the environment has been 
implicated in the aetiology of GDM (Elobeid and Allison 2008, Newbold et al 2009, Rubin 
and Sato 2009).  A connection at the epidemiologic level in humans has been recently 
proposed for dioxin, an environmental contaminant that acts through other than estrogen 
receptors (ERs) as an endocrine disruptor (Bertazzi et al 2001, Remillard et al 2002). 
3.4 Autoimmunity and Treg in GDM 
Autoimmune phenomena associated with type 1 diabetes mellitus (DM) can also be 
detected in a subgroup of women with GDM. Islet autoantibodies are present in sera from 
women with GDM with variable frequency. Distinct phenotypic and genotypic features may 
be recognised in this subset of women with GDM, which are representative of a distinct 
clinical entity. Women with previous autoimmune GDM may be candidates for potential 
immune intervention strategies (Mauricio et al 2001). Normal activity of Treg 
subpopulations are disrupted in GDM by mechanisms that threaten pregnancy and may 
contribute to other features of the disorder, with higher percentages of activated T cells than 
a matched population of healthy pregnant women. BuChE detoxifies anticholinesterases 
(AC) that are known to threaten pregnancy and one or more of these fetotoxins adversely 
impacts pregnancy outcome through a mechanism that may include Treg cells. In normal 
pregnancy, there is correlation between Treg activity and BuChE, whereas in women in 
whom adequate correlation between Treg cells and BuChE activity is not achieved 
(Mahmoud et al 2003, Mahmoud et al 2006, Mahmoud et al 2008, Saito et al 2005), there is 
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failure of effective clearance of toxicants which adversely affect maternal 
immunomodulation in ways that can lead to GDM and other pregnancy-threatening 
conditions (Baccarelli et al 2002, Bertazzi et al 2001, Eskenazi et al 2004, Lappas et al 2010, 
Maussolie et al 1992,  Remillard et al 2002).  
3.5 Genetics of gestational diabetes mellitus  
There is very little published data about the genetic basis for gestational diabetes mellitus 
(GDM) (Watanabe et al 2007). However, there is evidence for clustering of type 2 diabetes 
and impaired glucose tolerance in families with a GDM (McLellan et al 1995) and evidence 
for higher prevalence of type 2 diabetes in mothers of women with GDM (Martin et al 1985).  
HLA DR3 and DR4 antigens are in higher frequency in women with GDM than in women 
with normal pregnancies. Furthermore, an association between variation in the insulin 
receptor (INSR) in Caucasian and African-American women with GDM has been reported 
(Ober et al 1989). A ǃ-cell defect is one of the primary characteristics of GDM and ǃ-cell 
function is a highly heritable trait(Watanabe et al 2007). 
4. Association between GDM and oxidative stress and diabetic complications 
Pregnancy is susceptible to oxidative stress and antioxidant defenses that can be altered in 
response to elevated levels of oxidative stress (Chen and Scholl 2005. Marfella et al 2001, 
Maxwell et al 1997).  
In GDM products of lipid peroxidation may be increased and antioxidant enzyme activities 
decreased and the oxygen free radicals may be involved in severe damage of cellular 
structure (Osawa andKato 2005, Twardowska-Saucha et al 1994) and pregnancy complicated 
by poor glycemic control is associated with a higher risk of embryopathies, spontaneous 
abortion and perinatal morbidity and mortality (Loeken 2006). Recently, Karacay et al (2010) 
demonstrated that plasma and serum maternal total antioxidant status (TAS) was 
decreased, while circulating levels of lipid peroxidation breakdown products (MDA) were 
increased  between 24 and 36 weeks of gestation, thus showing  that increased oxidative 
stress and reduction in antioxidant defense mechanisms may contribute to disease processes 
in GDM (Bertazzi et al 2001, Karacy et al 2010, Rustemeijer et al 2001). Carine et al (1993) 
and Zachara et al (1993) found no differences in glutathione peroxidase (GPX) levels 
between pregnant women at third trimester and non-pregnant women, but recent studies 
have demonstrated an association between GDM and impaired SOD activities and enhanced 
circulating lipid metabolite levels such as MDA (Grissa et al 2007). Catalase, the main 
regulator of hydrogen peroxide metabolism is involved in Glut 4 expression, insulin 
secretion, insulin signaling, protein tyrosine phosphatase regulation, and glucose transport 
stimulation (Goth et al 2005, Mueller et al 1997). Catalase is important in antioxidant defense 
against hydrogen peroxide and  increased risk of diabetes has been reported in hereditary 
catalase deficiency (Goth and Eaton 2000, Sindhu et al 2004). 
5. Biology of BuChE  
The enzyme cholinesterase is present in all mammals and two classes have been identified 
:acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase (BChE);  AChE exists in 
the central nervous system, platelets and the erythrocyte membrane, while BChE is more 
abundant in the serum and is synthesized by the liver (Daresh et al 2003). BuChE was 
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named “pseudocholinesterase” by Mendel and Rudney in 1943 (1943). Human plasma 
BuChE (EC 3.1.1.8) is a globular, tetrameric serine esterase with a molecular mass of ≈340 
kDa that is stable in plasma with a half-life of 12 days (Lockridge et al 1987, Ostergaard et al 
1988).  BuChE acts on hydrophilic and hydrophobic choline esters, and that it hydrolyzes a 
variety of xenobiotics as shown in Table 2. Previous studies have reported a significant 
association between the serum BuChE activity and obesity, coronary artery disease, serum 
levels of triglycerides (TG), very low-density lipoprotein, low-density lipoprotein and Apo 
lipoprotein B, type 2 diabetes mellitus and the hepatic fat content (Alcantara et al 2005, 
Cucuianau et al 1999, Randell et 2005, Sridhar et al 2005). At variance with AChE-S, BuChE 
attenuates the fibril-formation process by the aromatic W8 residue. This residue can form 
heteroaromatic complexes with soluble monomeric or low-oligomeric Aǃ conformers. That 
replacement of tryptophan to a polar residue abolishes the attenuation of Aǃ fibril formation 
is fully compatible with this hypothesis. AChE mRNA is 20-fold more abundant than 
BuChE mRNA. In human blood, however, BuChE, at 50 nM, is 3-fold more abundant than 
AChE (Daresh et al 2003).  
 
BuChE protein or mRNA has been found in almost every tissue of the body, showing that 
it has a function. 
1. Acetylcholine and butyrylthiocholine hydrolysis. 
2. Protection from neurotoxins 
- OP nerve agents 
- OP pesticides 
- Carbamate pesticides 
- Alzheimer drugs-donepezil and rivastigmine 
- Physostigmine in the calabar beans 
-  Cocaine from Erythroxylum coca plant 
- Solamidine from green potatoes 
- Luperzine A from the club moss 
- Anatoxina in the blue green algae. 
3. Hydrolysis of short-acting muscle relaxants 
- Succinylcholine 
4. Not clear yet 
-  Glucose and lipid metabolism   
Table 2. Functions of BuChE 
5.1 Genetics of BuChE 
The complete amino acid sequence of human serum BuChE have been described (Daresh et 
al 2003). The human butyrylcholinesterase (BuChE; EC 3.1.1.8) is encoded by a single gene 
which corresponds to the E1 locus BuCHE gene (3q26.1-q26.2) which presents four exons 
(Arpagaus et al 1993), with more than 70 already-described variants (Pantuck 1993, Souza et 
al 2005). Data from dizygotic twin pairs has shown linkage on chromosome 3 at the location 
of the BuChE gene and also on chromosome 5. BuChE is found in human plasma, either in 
homomeric viz. monomers (G1), dimers (G2), trimers (G3) and tetramers (G4), or 
heteromeric forms associated with other substances, such as albumin (G1-ALB) (Masson et 
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al 1989, Pantuck 1993).  The BCHE-K variant has been reported to show allelic association 
with Alzheimer disease (AD) in subjects who are also carriers of the e4 allele of 
apolipoprotein E (APOE), especially in subjects over the age of 75 years. The K variant, is 
carried on one allele by one of four persons (Rao et al 2006). As BuChE is found common to 
both Alzheimer's disease and diabetes; it may play an etiological role via influencing insulin 
resistance and lipid metabolism (Arpagaus et al 1990, Lockridge et al 1987, Rao et al 2006). 
Similarly patients with Alzheimer's disease are more vulnerable to developing impaired 
fasting glucose and type 2 diabetes mellitus (Janson et al 2004, Johansen et al 1991) 
5.2 BuChE and placental development 
In utero exposure to poisons and drugs (e.g., anticholinesterases, cocaine) is frequently 
associated with spontaneous absorption and placental malfunction. The major protein 
interacting with these compounds is butyrylcholinesterase (BuChE), which attenuates the 
effects of such xenobiotics by their hydrolysis or sequestration. Sternfeld and Associates 
(1997) studied BuChE expression during placental development. RT-PCR revealed both 
BuChE mRNA and acetylcholinesterase (AChE) mRNA throughout gestation. Maximum 
butyrylcholinesterase activity has shown in week 12. In rat placenta, BuChE activity on 
gestational day 21 reached 150% of the level on gestational day 16. BuChE detoxifies 
anticholinesterases (AC) and other toxins including free radicals that are known to threaten 
pregnancy (Hollander et al 2007, Maxwell et al 1997, Osawa and Kato 2005, Twardowska-
Saucha et al 1994).  There is evidence that Kuwaiti women experiencing disorders of 
pregnancy like preeclampsia and diabetes mellitus in pregnancy exhibited lower serum 
activity of BuChE (Mahmoud et al 2003, Mahmoud et al 2006, Mahmoud et al 2008). 
6. Clinical role of BuChE 
BuChE (BuChE; EC 3.1.1.1.8) has well-defined pharmacologic functions:  
BuChE and anaesthetic muscle relaxants: Mivacurium and succinylcholine are short-acting 
neuromuscular blocking drugs ideal for short surgical procedures as muscle relaxants used 
in anesthetic practice. The brief duration of action depends on rapid hydrolysis by plasma 
cholinesterase (Jensen et al 1991Pantuck 1993). An inherited or acquired deficiency of 
plasma BuChE can prolong the effect of mivacurium. When there is a deficiency of this 
enzyme due to the presence of one or more atypical alleles, mivacurium and succinylcholine 
are not properly metabolized and thus muscle paralysis can last for several hours (Davis et 
al 1997, Goudsouzian et al 1993, Petersen et al 1993, Savarese et al 1997). 
6.1 Factors affecting BuChE activity 
Different disease states and/or drug administrations may decrease BuChE activity.; such as 
extremes of age, pregnancy, renal and liver disease, malignancy, burns, chronic 
debility/malnutrition, myocardial infarction/cardiac failure, collagen diseases, myxedema, 
poisoning and protein energy malnutrition. Drugs that inhibit the enzyme’s activity include 
acetylcholinesterase inhibitors (neostigmine, pyridostigmine, physostigmine, and 
edrophonium), anticholinesterases (especially echothlophate), cytotoxic agents (such as 
cyclophosphamide), steroids, ester-type local anesthetics, hexafluorenium, pancuronium, 
oral contraceptives and sertraline (Klein-Schwatz and Anderson 1996, MacQueen et al 2001, 
Muller et al 2002).  
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6.2 BuChE and Organophosphatase (OP) and cocaine hydrolysis 
Another reason for continued interest in serum cholinesterase is its extraordinary sensitivity 
to organophosphate ester. Systemic administration of BuChE, at a dose sufficient to increase 
plasma BuChE levels 400-fold (5000 I.U.; i.v.), has been shown to significantly decrease 
cocaine-induced locomotor activity in rats over a 120-min session (Carmona et al 1997).  The 
identification of BuChE variants that exhibit increased cocaine hydrolysis activity provides 
treatment options for cocaine-induced conditions such as cocaine overdose and addiction 
(Arkhypova et al 2004, Lockridge et al 2005), Lynch et al 1997).   
6.3 BuChE activity and dyslipidemia and metabolic syndrome  
Serum levels of BuChE are affected by dietary fat, obesity, hyperlipidemia and diabetes 
mellitus, alcohol and many drugs are known to increase BuChE activity (Alcantara et al 
2005, Stefanello et al 2005, Vrdoljaki et al 2005). Therefore, BuChE may have a role in the 
altered lipoprotein metabolism in hypertriglyceridaemia associated with diabetes mellitus 
and insulin resistance. BuChE is synthesized in the liver, and is present in plasma and to a 
lesser extent in adipose tissue, small intestine and smooth muscle. Sridhar et al (2005) 
measured the serum level of BuChE levels in persons with type 2 diabetes mellitus and 
demonstrated a negative correlation between BuChE and serum total cholesterol and LDL 
cholesterol, thus further confirming that BuChE may be involved in lipid metabolism.  
6.4 Serum determination of BuChE 
The application of the techniques of molecular genetics has permitted precise identification 
of plasma cholinesterase variants and has resulted in the discovery of previously 
unrecognized variants. Serum BuChE activity has been determined by the method of Ellman 
et al (1961). In addition to colorimetric methods, HPLC, Electrophoresis, Immunoassay 
methods (ELIZA) and Biosensor methods have been used. 
6.5 Production of human BuChE 
Human BuChE has been obtained from human plasma by a large scale purification technique 
(Lockridge et al 2005). This procedure is severely limited by the volume of human plasma 
needed and may not be cost effective and it may not yield a sufficient amount of enzyme 
purified commercially.  Large quantities of BuChE are needed for effective prophylaxis and 
treatment of exposure. BuChE has a broad spectrum of activity, a relatively long half-life, and 
few physiological side effects. Producing recombinant BuChE (rBuChE) is an alternative to 
purification of the enzyme from human plasma. A number of studies have shown the 
feasibility of producing large quantities of BuChE in transgenic animals (goats) and transgenic 
edible plants for prophylaxis or treatment of humans exposed to OP agents (Lockridge et al 
2005, Podoly et al 2008, Protexia 2011) and cocaine overdose or addiction (Om et al 1993). 
7. Association between BuChE and oxidative stress  
Stefanello et al. (2005) investigated the effect of homocysteine administration on BuChE 
activity in the serum of rats. Acute and chronic administration of homocysteine significantly 
decreased BuChE activity but administration of vitamins A and C prevented the reduction 
of the activity.  Delwing et al (2005) observed that acute proline administration provoked a 
22% increase in BuChE activity in the serum of rats. In a similar study, Wyse et al (2004) 
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demonstrated that vitamins E and C reversed the inhibition of BuChE activities provoked by 
arginine in the serum of rats, thus indicating that the reduction of BuChE activities caused 
by arginine was probably mediated by oxidative stress. In a similar fashion, Cederberg et al. 
(2001) have shown that combined treatment with vitamins E and C decreased oxidative 
stress and improved fetal outcome in experimental pregnancy. From the foregoing, BuChE 
may yet be another mechanism in the fight against oxidative stress.  
7.1 Mechanisms of the association between BuChE and oxidative stress in GDM 
In a recent report, we (Omu et al 2010) showed that BuChE activity was elevated in the serum 
and placenta in normal pregnancy as compared to diabetic cohorts (p < 0.01) and there was a 
higher activity level in gestational and type 2 diabetes on insulin (p<0.05) compared with diet 
controlled. Conversely, there was higher MDA and lower antioxidant activity in diet versus 
insulin controlled diabetes (p < 0.01). Both serum and placental BuChE activity showed a 
strong inverse correlation with MDA (r = -0.876, p < 0.001) and (r = - 0.542, p < 0.01), but strong 
positive correlation with total antioxidant activity in serum (r = 0.764, p < 0.001) and placenta 
(r = 0.642, p < 0.01). These results are therefore consistent with a mechanism in which BuChE 
acts to scavenge free radicals in the presence of oxidative stress. An interesting finding in the 
study was the higher BuChE activity in the two groups of insulin-treated diabetics compared 
with their counterparts on diet. This led to the speculation that the diabetic patients on diet 
only might not have had satisfactory glycogenic control. However, BuChE did not show any 
correlation with enzymatic antioxidants SOD and GPX (Omu et al 2010); indirectly showing 
that BuChE was not inhibiting MDA through the antioxidants pathway. While this is mere 
speculation, it has important clinical implication if the association between BuChE and 
glycemic control is confirmed by future research. HbA1c has been used for monitoring 
diabetic control of the last 3 months, maybe BuChE could be used for short term or immediate 
monitoring of glycemic control. BuChE is already a known marker of metabolic syndrome 
(Sridhar et al 2005), and its activity is high in human term placenta (Hahn et al 1993, Lappas et 
al 2010, Omu et al 2010, Simone et al 1994, Sternfield et al 1997). The lower level of placental 
BuChE activity compared with serum, shown in the study may be as a result of a high level of 
fetotoxic agents, including free radicals (oxidative stress), in the placenta that BuChE 
metabolises by hydrolysis.  
7.2 Advanced glycation end-products (AGE), reactive oxygen species (ROS) and 
BuChE  
Glycation reactions lead to the production of reactive oxygen species (ROS), which are harmful 
to cellular metabolism and cause cell damage. There are no research data of any relationship 
between AGE and BuChE activity. While it is highly speculative, BuChE may protect 
pregnancy from the effect of oxidative stress by preventing the (formation) of reactive oxygen 
species formation  by hydrolyzing and inactivating advanced glycation end products 
upstream. This hypothesis is consistent with the finding of lack of correlation between BuChE 
and SOD and GPX (Omu et al 2010). 
8. Gestational diabetes mellitus and BuChE 
Another contributor to toxicant-induced immune dysregulation as a contributor to GDM 
might be that reactive products of inflammation expressed by the maternal immune system 
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in response to paternal antigens adversely affect maternal health in ways that increase 
susceptibility to diabetes, thereby leaving women with naturally lower BuChE levels at 
greater risk for gestational and possibly Type 2 diabetes. The relationship between size of 
activated lymphocyte cohorts and BuChE activity in the RPL versus healthy cohorts  
provides additional support for the hypothesis that both immune activation and BuChE 
activity may be tied to some as-yet-unidentified systemic effector. For example, our 
observation of positive correlation between the frequency of CD3+CD16+CD56+ cells and 
BuChE activity in healthy individuals but not RPL-afflicted subjects would be expected if 
these cells which are often pathogenic, were expanded in response to environmental toxins. 
In the type 2 diabetes mellitus population serum BuChE activity has been correlated with 
insulin sensitivity (r = -0.51, P < 0.001). BuChE activity was elevated in the serum and 
placenta in normal pregnancy versus diabetic cohorts (p < 0.01) and there was a higher 
activity level in gestational and type 2 diabetes on insulin (p < 0.05) compared with diet 
controlled (Omu et al 2010, Mahmoud et al 2003, Mahmoud et al 2006, Mahmoud et al 2008, 
Rustemeijer et al 2001) 
8.1 BuChE and congenital anomalies 
BuChE may also play a significant role in congenital anomalies. Dupont et al. (1995) have 
reported that fetuses with anencephaly and open spinal bifida and gastroschisis revealed 
clearly dense band of BuChE in the amniotic fluid. A causative role for elevated free fatty 
acid (FFA) levels in the development of microvascular complications remains to be 
established, however. Increased levels of FFAs are positively correlated with both insulin 
resistance and the deterioration of ß-cell function in the context of concomitant 
hyperglycemia. These latter effects may result from oxidative stress (Evans et al 2003).  
9. Future directions and hypotheses of connection between BuChE and GDM 
There is need to explore a number of hypotheses to fully unravel the connection between 
GDM and BuChE through aggressive research efforts.  
9.1 Role of estrogen alpha receptor and BuChE in pathogenesis of gestational 
diabetes 
High levels of estrogens in the second half of pregnancy with high estrogen receptor alpha 
(ER ) lead to deterioration of glucose metabolism. Estrogens may reduce the risk of AD 
through enhancing or preserving cholinergic neurotransmission, and aromatase, the 
product of the CYP19 gene, is a critical enzyme in the peripheral synthesis of estrogens. 
There is evidence to suggest that the CYP19 and BuChE polymorphisms may interact in 
determining the risk of AD. Carriers of both the ER-a P/P genotype and the BuChE K 
variant would have decreased risk of developing AD (Conbarros et al 2007). ER alpha 
signaling activity and glucose metabolism may therefore be affected by CYP19 and BuChE 
polymorphisms. 
9.2 Advanced glycation end products hydrolysis by BuChE 
Advanced glycation end products may inhibit BuChE activities, probably as a result of the 
hydrolyzing effect of the latter, upstream before they cause oxidative stress.  
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10. Concluding remarks 
Unraveling the connection between GDM and BuChE has become a veritable area of 
research in the pathogenesis, screening, prevention and management. With the large scale 
purification of BuChE from human plasma, milk of transgenic goats and edible transgenic 
plants and its suitability for prophylactic and therapeutic protection against cocaine and 
nerve agent toxicity, the way for therapeutic use in humans, especially during complicated 
pregnancy needs urgent scientific exploration as BuChE may have an important protective 
role in normal and diabetic pregnancy by reducing oxidative stress and therefore reduce 
diabetes induced complications. Mechanisms for attenuation of the effects of oxidative stress 
by BuChE should be investigated. Heritable factors may be an underlying biological thread 
in the connection between GDM and BuChE. In addition, genetic variants of  BuChE exist, 
which may play a role in biological manifestation of individuals. Identification of such 
sequences would provide leads for further understanding of aetiological, therapeutic or 
prognostic aspects of Gestational diabetes mellitus. If future studies reveal that immune 
dysregulation is a contributor to the pathogenesis of GD or DM, characterization of the 
mechanisms will open additional avenues to development of therapeutic approaches to both 
disorders. 
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